GeekWire

MARCH 8, 2022

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We

Biotechnology 107

Biotechnology .Net Programming Company 107

GeekWire

AUGUST 12, 2024

To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. (NASA Photo / Dominic Hart) The Mars Society says it’s making progress on launching a startup incubator in the Seattle area, with artificial intelligence and biotech as its first targets. Its long-term goal?

Biotechnology 123

Biotechnology Chemicals Artificial Intelligence Engineering 123

GeekWire

JUNE 11, 2024

Levitate Bio’s CEO Sam DeLuca, left, and Karen Khar, executive vice president of sales and business development. David Baker, director of the UW’s Institute for Protein Design, runs the lab that developed Rosetta and is an advocate for open-source tools. Tech companies are really good at what they do.

Software 112

Software Software Development Company 112

GeekWire

FEBRUARY 15, 2022

Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Progress on a collaboration with biopharma company Nykode Therapeutics to support the development of a T-cell based COVID-19 vaccine. Adaptive moved into its new headquarters in September. GeekWire Photo / Charlotte Schubert).

Biotechnology 95

Biotechnology .Net Development Study 95

GeekWire

JULY 14, 2020

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock — 6 million of its own, and 2 million from an investor — to help accelerate the company’s work.

Biotechnology 66

Biotechnology Development Microsoft Report 66

GeekWire

JANUARY 13, 2021

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. Sana, which is developing gene and cell therapies that could be used to combat a variety of diseases, previously raised more than $700 million in venture capital. Sana CEO Steve Harr (Sana photo). stake in Sana.

Biotechnology 138

Biotechnology Applications .Net Company 138

GeekWire

OCTOBER 19, 2021

Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.

Biotechnology 127

Biotechnology System Programming Engineering 127

GeekWire

NOVEMBER 10, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19. The company also is developing T-Detect COVID , a T-cell-based test for identifying past COVID-19 infections.

Biotechnology 70

Biotechnology Pharmaceuticals Development System 70

GeekWire

SEPTEMBER 21, 2021

Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. The company ramped up rapidly as the pandemic accelerated, supporting the development of COVID-19 vaccines.

Biotechnology 98

Biotechnology Real Estate Analysis Research 98

TechSpot

JULY 24, 2024

The UK Space Agency and BiologIC Technologies are partnering to develop advanced biotechnologies, including vaccines and gene therapies, for space manufacturing.

Biotechnology 111

Biotechnology Research Development 111

GeekWire

SEPTEMBER 26, 2024

Symbl CEO Surbhi Rathore said in a LinkedIn post that Senthivel “has been instrumental in developing foundational infrastructure that serves across industries.” Senthivel was most recently CTO for GE HealthCare and was previously part of AI engineering leadership at Amazon Web Services, among other roles. ” Ken Suzuki.

CTO 101

CTO Healthcare Biotechnology Nonprofit 101

GeekWire

JULY 7, 2021

The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Development 141

Development Biotechnology Pharmaceuticals .Net 141

GeekWire

DECEMBER 20, 2021

Alexandria Real Equities , a life sciences real estate developer, has bought a 5.2-acre Alexandria bought the property from Bellevue company Pine Forest, which has been planning a large mixed-use development for the site. Alexandria is developing a life sciences hub at Seattle’s almost three-acre Mercer Mega Block.

Real Estate 117

Real Estate Development Biotechnology Journal 117

GeekWire

JUNE 4, 2020

Investors are betting big on the company, which announced a giant $85 million Series B investment round Thursday to help fuel late-stage development of its lead therapeutic candidate called NDX-1017. Depending on the development and approval process, Kawas said the drug could come to market within 2-to-3 years. billion in 2018.

Development 145

Development Biotechnology Research Healthcare 145

GeekWire

OCTOBER 9, 2024

Baker and his colleagues developed an early protein design tool and made the code available through a consortium called Rosetta Commons. Baker’s research contributed to the development of the world’s first computationally designed protein medicine, a vaccine for COVID-19 pioneered by colleagues at UW Medicine.

Biotechnology 140

Biotechnology Pharmaceuticals Artificial Intelligence Research 140

GeekWire

JULY 2, 2020

OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. The researchers said they have selected the two most promising DNA sequences for further testing. Researchers at OncoSenX are using Fusogenix for cancer research on the treatment of solid tumors.

Research 145

Research Pharmaceuticals Biotechnology Development 145

GeekWire

MAY 27, 2021

New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing preclinical therapies that target and kill damaged cells that have been biologically turned off or are “senescent” and supposed to die. Oisín Photos). Oisín has raised a total of $9.5

Development 115

Development Biotechnology Travel Study 115

GeekWire

SEPTEMBER 1, 2020

Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. Lumen is led by Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Research Institute.

Development 118

Development Biotechnology Travel Programming 118

GeekWire

MAY 21, 2020

The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said CEO John Mulligan. Another Seattle biotech company, Nautilus Biotechnology, announced a $76 million funding round Thursday. It is focused initially on immuno-oncology applications.

Development 94

Development Biotechnology Microsoft Applications 94

GeekWire

MARCH 8, 2023

(Wexford Science + Technology Image) The University of Washington will move ahead with a building envisioned as a gateway into a reimagined part of its Seattle campus after prevailing in a lawsuit brought by a prominent developer. The UW chose Baltimore-based Wexford Science + Technology to develop the project.

Energy 97

Energy Real Estate Research Development 97

GeekWire

AUGUST 5, 2021

Tadataka Yamada, a pioneer in drug and vaccine development who helped forge numerous biotech companies and spent six years at the Bill and Melinda Gates Foundation as head of global health, died Wednesday morning of natural causes at his home in Seattle. Tadataka “Tachi” Yamada. Twitter Photo via @TachiYamada).

Pharmaceuticals 127

Pharmaceuticals Development Biotechnology Industry 127

GeekWire

AUGUST 26, 2021

Diagnostics startup ID Genomics will accelerate its development of a quick test for variants of the COVID-19 virus with a new grant from the U.S. In addition to developing the CovNET rapid test, ID Genomics will launch a next-day sequencing service for variants within the next few weeks. National Institutes of Health.

Development 127

Development Biotechnology Small Business Analysis 127

GeekWire

JANUARY 14, 2022

The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. government has been buying to fight Omicron.

Biotechnology 104

Biotechnology Government Research Development 104

GeekWire

DECEMBER 6, 2021

The news: Seattle-based protein engineering company Cyrus Biotechnology has raised $18 million and acquired Orthogonal Biologics , a spinout from the University of Illinois at Urbana Champaign, which is developing a COVID-19 therapeutic. Cyrus CEO Lucas Nivon. Cyrus Photo).

Software 101

Software Software Development Mobile 101

GeekWire

JULY 27, 2020

Chad Robins, CEO of Adaptive Biotechnologies, speaks at the site of the company’s future corporate headquarters in Seattle, standing in front of the final piece of structural steel before it’s put into place. Stephen Brashear/AP Images for Adaptive Biotechnologies). Stephen Brashear/AP Images for Adaptive Biotechnologies).

Biotechnology 110

Biotechnology Real Estate Industry Microsoft 110

GeekWire

APRIL 12, 2023

Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.

Biotechnology 98

Biotechnology Policies Energy Meeting 98

GeekWire

AUGUST 23, 2021

Since early July alone, three of those companies went public: drug discovery platform company Absci raised $200 million, vaccine developer Icosavax raised $180 million and nervous system therapeutics company Eliem Therapeutics raised $80 million. It’s an unprecedented trend. billion, according to EndpointsNews.

Biotechnology 125

Biotechnology Company Trends Software 125

GeekWire

NOVEMBER 9, 2023

Adaptive Biotechnologies CEO Chad Robins speaks at the GeekWire Summit in 2019. He said the businesses are at different stages of maturity, with different capital and development needs. Robins said they’ve been talking for the past 18 months about their two distinct business opportunities.

Biotechnology 97

Biotechnology Real Estate .Net Conference 97

GeekWire

JULY 29, 2021

The company, a spin-out from the University of Washington’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Biotechnology 138

Biotechnology Company Pharmaceuticals Research 138

GeekWire

APRIL 15, 2021

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 99

Biotechnology Education Web Services Insurance 99

GeekWire

JUNE 30, 2021

based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. Absci aims to circumvent current processes for developing protein-based drugs, which often require manufacture in mammalian cells, a cumbersome and difficult method. Absci Photo).

Company 130

Company Biotechnology .Net Programming 130

GeekWire

NOVEMBER 19, 2020

Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. ” Umoja is one of several companies in the Seattle region developing immunotherapy-related technologies. Umoja Biopharma CEO Andy Scharenberg. Umoja Photo).

Biotechnology 144

Biotechnology Research CTO Development 144

GeekWire

MARCH 18, 2024

Clockwise, from top left: SEngine Precision CEO Carla Grandori; Joon Care CEO Emily Pesce; FlavorCloud CEO Rathna Sharad; AltPep CEO Valerie Daggett; and Strella Biotechnology CEO Katherine Sizov. The 4-year-old company raised $52.9 million in a Series B round last year. Grandori previously founded Cure First, another Seattle biotech startup.

Company 94

Company Biotechnology Chemicals Survey 94

GeekWire

JULY 18, 2023

After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a gene therapy startup.

Biotechnology 86

Biotechnology Company Development 86

GeekWire

MARCH 8, 2023

(Wexford Science + Technology Image) The University of Washington will move ahead with a building envisioned as a gateway into a reimagined part of its Seattle campus after prevailing in a lawsuit brought by a prominent developer. The UW chose Baltimore-based Wexford Science + Technology to develop the project.

Energy 58

Energy Real Estate Research Development 58

GeekWire

OCTOBER 9, 2024

Phase Genomics has developed technology for sequencing DNA from wide-ranging and tricky to study organisms. Other former positions include leadership roles at the Gates Foundation and directing the global drug development program at PATH. Susan Wyrick of Sana Biotechnology.

Biotechnology 96

Biotechnology Microsoft Dell Education 96

GeekWire

APRIL 18, 2023

The category highlights pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for bettering our lives or improving the healthcare system. Good Therapeutics Graphic) Developing therapeutics that are active only where they are needed in the body has the potential to reduce toxic side effects.

Biotechnology 120

Biotechnology Healthcare Development Software 120